Headlines about Humana (NYSE:HUM) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Humana earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news headlines about the insurance provider an impact score of 45.3723634310554 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern’s scoring:
- Humana Sees Relative Strength Rating Improve To 71 (finance.yahoo.com)
- Humana Inc. to Present at the 36th Annual JP Morgan Healthcare Conference – Digital Journal (digitaljournal.com)
- Humana Inc (HUM) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- 4 Health Care Stocks Prescribed As Buys By Goldman Sachs (finance.yahoo.com)
- Humana (HUM) Stock: Gaining On Takeover Chatter (cnafinance.com)
Shares of Humana (HUM) traded up $5.97 during trading hours on Friday, hitting $264.33. 1,226,478 shares of the company were exchanged, compared to its average volume of 1,151,000. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35. The stock has a market cap of $37,760.00, a P/E ratio of 20.81, a P/E/G ratio of 1.66 and a beta of 0.88. Humana has a 52 week low of $186.25 and a 52 week high of $264.90.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.27 by $0.12. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $13.41 billion. Humana had a net margin of 3.49% and a return on equity of 15.99%. The firm’s quarterly revenue was down 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $3.18 EPS. analysts predict that Humana will post 11.63 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend is Thursday, December 28th. Humana’s dividend payout ratio (DPR) is currently 12.60%.
Humana declared that its Board of Directors has authorized a share buyback program on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the insurance provider to purchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.
Several analysts have recently issued reports on HUM shares. BMO Capital Markets upped their target price on shares of Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $242.00 target price (down previously from $245.00) on shares of Humana in a research note on Thursday, November 9th. Cowen reiterated a “buy” rating and issued a $285.00 target price on shares of Humana in a research note on Wednesday, December 13th. Credit Suisse Group reduced their target price on shares of Humana from $256.00 to $246.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. Finally, Zacks Investment Research lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Twelve research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $258.62.
In related news, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $245.97, for a total value of $412,983.63. Following the transaction, the senior vice president now directly owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jody L. Bilney sold 7,054 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the completion of the transaction, the senior vice president now directly owns 11,704 shares in the company, valued at $2,901,304.56. The disclosure for this sale can be found here. Insiders sold a total of 10,115 shares of company stock worth $2,501,627 over the last three months. 0.80% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: This report was reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2018/01/06/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-humana-hum-share-price.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.